SCHEMBL15613005

SCHEMBL15613005

CC(C)(C)OC(=O)N(CCNC(=O)OCc1ccccc1)CCNC(=O)OCc1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.55
LMNA P02545 1/20 0.55
HTT P42858 1/20 0.52
SYK P43405 1/20 0.51
MAPT P10636 2/20 0.50
L3MBTL1 Q9Y468 3/20 0.49
HDAC3 O15379 1/20 0.48
HDAC1 Q13547 1/20 0.48
HDAC2 Q92769 1/20 0.48
NCOR2 Q9Y618 1/20 0.48
IDO1 P14902 1/20 0.47
CCR6 P51684 1/20 0.47
PAX8 Q06710 1/20 0.47
TGM2 P21980 1/20 0.47
KEAP1 Q14145 2/20 0.46
NFE2L2 Q16236 2/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
BACE1 P56817 2/20 0.46
TPSAB1 Q15661 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17190637 0.95 SMN1; SMN2 (0.50) SMN1; SMN2LMNAHTTSYKMAPT
SCHEMBL34475270 0.95 SMN1; SMN2 (0.50) SMN1; SMN2LMNAHTTSYKMAPT
SCHEMBL2189134 0.94 SMN1; SMN2 (0.49) SMN1; SMN2LMNAHTTSYKMAPT
SCHEMBL10521902 0.93 HTT (0.51) SMN1; SMN2LMNAHTTSYKMAPT
SCHEMBL15716592 0.93 SYK (0.55) SMN1; SMN2LMNAHTTSYKMAPT
SCHEMBL9554886 0.92 SMN1; SMN2 (0.49) SMN1; SMN2LMNAHTTSYKMAPT
SCHEMBL12417860 0.91 SMN1; SMN2 (0.49) SMN1; SMN2LMNAHTTSYKMAPT
SCHEMBL31421118 0.90 SMN1; SMN2 (0.48) SMN1; SMN2LMNAHTTSYKMAPT
SCHEMBL22123600 0.89 HTT (0.53) SMN1; SMN2LMNAHTTSYKMAPT
SCHEMBL3485350 0.89 SMN1; SMN2 (0.66) SMN1; SMN2LMNAHTTSYKMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2887963-B1 COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS ARDELYX INC (US) 2017-07-19 EP disclosed
US-20160221971-A1 DI-MACROCYCLES LUMIPHORE, INC. (US) 2016-08-04 US disclosed
US-20160221971-A1 DI-MACROCYCLES LUMIPHORE, INC. (US) 2016-08-04 US disclosed
WO-2014029984-A1 COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS ARDELYX, INC. (US) 2014-02-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160221971-A1 DI-MACROCYCLES DLD, NDC1, MCL1 SMN1; SMN2 3304/4885LMNA 3243/4885HTT 312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.